NATCO Pharma Full Year 2025 Earnings: Misses Expectations

NATCO Pharma (NSE:NATCOPHARM) Full Year 2025 Results

Key Financial Results

• Revenue: ₹47.8b (up 20% from FY 2024).
• Net income: ₹18.9b (up 36% from FY 2024).
• Profit margin: 39% (up from 35% in FY 2024). The increase in margin was driven by higher revenue.
• EPS: ₹105 (up from ₹77.35 in FY 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

NATCO Pharma Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 3.2%. Earnings per share (EPS) also missed analyst estimates by 3.2%.

Looking ahead, revenue is expected to decline by 17% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in India are expected to grow by 10%.

Performance of the Indian Pharmaceuticals industry.

The company's shares are up 1.9% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 2 warning signs for NATCO Pharma (of which 1 can't be ignored!) you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.